Stryker has received FDA 510(k) clearance for its OptaBlate BVN nerve ablation system, expanding its offerings in advanced pain therapy. Designed to deliver long-lasting relief for chronic vertebrogenic low back pain, the minimally invasive system targets the basivertebral nerve, a common but often undertreated source of pain.
OptaBlate BVN combines radiofrequency ablation and precise vertebral access with features like a steerable curved introducer and microinfusion technology to maintain tissue hydration and reduce errors during ablation. The system can create a 1 cm lesion in just seven minutes.
Dr. Jad Khalil emphasized its potential: “For many patients, BVNA offers meaningful improvement and can help avoid more aggressive treatments like surgery.”
Stryker’s Kristen Berg added, “Our legacy providing solutions to reduce pain now continues with OptaBlate BVN, addressing the underserved population suffering from chronic vertebrogenic lumbar pain.”
Follow MEDWIRE.AI for breakthroughs in spine care and interventional pain treatment.
